Drug Pipeline

Lorlatinib Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
13
Active Studies
6
Recruiting
1
Phase 3
9
Top Sponsors
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-15 NCT07556549
A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese…
overall status: "Not Yet Recruiting" → "Active Not Recruiting"
New Trial Filings, Last 30 Days
First PostedTrialPhaseStatus
2026-06-01 NCT07617337 AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer Phase 1 Not Yet Recruiting
Active Studies by Phase
Phase 4
1
Phase 3
1
Phase 2
3
Phase 1/2
1
Phase 1
1
Early Phase 1
1
Not specified
5
Active Trials
NCT IDTitleConditionStatus
Phase 4
NCT06282874 Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases Carcinoma, Non-Small-Cell Lung Active, Not Recruiting
Phase 3
NCT03126916 Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With… Ganglioneuroblastoma Recruiting
Phase 2
NCT07415005 Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung… Advanced Non-Small Cell Lung Cancer Recruiting
NCT05740943 Induction Lorlatinib in Stage III Non-small Cell Lung Cancer Stage III NSCLC Active, Not Recruiting
NCT05297890 A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer Active, Not Recruiting
Phase 1/2
NCT06007937 A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer Non Small Cell Lung Cancer Recruiting
Phase 1
NCT07617337 AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer ALK Positive Non-small Cell Lung Cancer Not Yet Recruiting
Early Phase 1
NCT06333899 Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion High Grade Glioma Recruiting
Not specified
NCT05599412 Post Marketing Surveillance(PMS) Study of Lorviqua in Korea Metastatic ALK+ Non Small Cell Lung Cancer Recruiting
NCT06487078 Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC… ALK+ Non-Small-Cell Lung Carcinoma Recruiting
NCT06678555 A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC)… Carcinoma, Non-Small-Cell Lung Active, Not Recruiting
NCT07567352 A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took… Non-Small-Cell Lung Active, Not Recruiting
NCT07556549 A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese… Non-Small Cell Lung Cancer ALK-positive Active, Not Recruiting
Sponsors Running Lorlatinib Trials
Disease Areas
Get alerts when Lorlatinib trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free